Fig 1: Doxorubicin chemoresistance is associated to H19-mediated upregulation of multidrug resistant proteins (MDR)In panels A and B, the levels of ABCB1 and ABCC4 mRNAs, and MDR1 and MRP4 proteins were quantified respectively by real-time RT-PCR and Western blot analysis in various cell lines as indicated. The mRNA levels were expressed as fold of parental MCF-7 control, and the data are the mean ± SEM of three to five independent experiments. The inserts on top of panels A and B, and panel C are representative Western blots analyses of MDR1, MRP4, XPD and TOPIIA proteins, respectively. β-actin was used as an internal loading control in Western blot analysis. Lanes in all Western blots are denoted as: lane 1 – MCF-7, lane 2 – MCF-7/Con1600, lane 3 – MCF-7/Dox1600, lane 4 – MCF-7/Dox/NC and lanes 5 to 7 – Three independent MCF-7/Dox/shH19 clones. *p < 0.05 compared to the corresponding controls.
Fig 2: Comparative analysis of the expression profile of BRCA2, XPD and APE1 proteins in the PBLs of individual HNSCC patients normalised with respect to the corresponding levels in the PBLs of age- and gender-matched controls. Each row denotes individual patients containing patient ID and each column represents the fold level of the designated protein. The highlighted patients IDs are the 12 HNSCC patients from whom tissue biopsy, blood and adjacent normal tissue were obtained for real-time analysis study.
Fig 3: Alterations in the level of BRCA2, XPD and APE1 proteins determined by (a): western blotting technique, with β-actin protein serving as loading control; and slot blotting followed by immunoprobing for (b): BRCA2, (c): XPD and (d): APE1 proteins in the PBLs of HNSCC patients compared to age- and gender-matched controls, with respective Ponceau S stained slot-blots serving as loading control. ** denotes statistical difference between controls and cases at p < 0.01; *** denotes statistical difference between controls and cases at p < 0.001. AU stands for arbitrary units.
Fig 4: Representative slot-blots showing (a): altered expression of BRCA2, XPD and APE1 proteins in the PBLs of HNSCC patients in comparison to those of age- and gender-matched controls. (b): The corresponding Ponceau S stained slot-blots to verify equal loading of samples.
Fig 5: Level of expression of (a): BRCA2, (b): XPD and (c): APE1 genes in the tumour tissue, blood and NAT of HNSCC patients, respectively, normalised with level of respective genes in age- and gender-matched control blood samples. AU stands for arbitrary units. Difference of gene expression among the stages was evaluated by one way ANOVA with Tukey’s post-hoc test and was not found to be statistically significant.
Supplier Page from Abcam for Anti-XPD antibody [EPR9675]